Literature DB >> 22579772

Astrocyte-derived GDNF is a potent inhibitor of microglial activation.

Sandra Moreira Rocha1, Ana Clara Cristovão, Filipa Lopes Campos, Carla Pais Fonseca, Graça Baltazar.   

Abstract

Neuroinflammation is recognized as a major factor in Parkinson's disease (PD) pathogenesis and increasing evidence propose that microglia is the main source of inflammation contributing to the dopaminergic degeneration observed in PD. Several studies suggest that astrocytes could act as physiological regulators preventing excessive microglia responses. However, little is known regarding how astrocytes modulate microglial activation. In the present study, using Zymosan A-stimulated midbrain microglia cultures, we showed that astrocytes secrete factors capable of modulating microglial activation, namely its phagocytic activity and the production of reactive oxygen species since both parameters were highly diminished in cells incubated with astrocytes conditioned media (ACM). Glial cell line-derived neurotrophic factor (GDNF), cerebral dopamine neurotrophic factor (CDNF) and brain-derived neurotrophic factor (BDNF), known to have a neuroprotective role in the nigrostriatal system, are among the candidates to be astrocyte-secreted molecules involved in the modulation of microglial activation. The effect of ACM on Zymosan A-induced microglial activation was abolished when the GDNF present in the ACM was abrogated using a specific antibody, but not when ACM was neutralized with anti-CDNF, anti-BDNF or with a heat-inactivated GDNF antibody. In addition, media conditioned by astrocytes silenced for GDNF were not able to prevent microglial activation, whereas supplementation of non-conditioned media with GDNF prevented the activation of microglia evoked by Zymosan A. Taken together, these results indicate that astrocyte-derived GDNF plays a major contribution to the control of midbrain microglial activation, suggesting that GDNF can protect from neurodegeneration through the inhibition of neuroinflammation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22579772     DOI: 10.1016/j.nbd.2012.04.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  63 in total

Review 1.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

2.  Decrease of glial cell-derived neurotrophic factor contributes to anesthesia- and surgery-induced learning and memory dysfunction in neonatal rats.

Authors:  Lingli Gui; Xi Lei; Zhiyi Zuo
Journal:  J Mol Med (Berl)       Date:  2017-02-17       Impact factor: 4.599

Review 3.  Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.

Authors:  Tingting Tang; Yong Li; Qian Jiao; Xixun Du; Hong Jiang
Journal:  Neurosci Bull       Date:  2017-03-23       Impact factor: 5.203

Review 4.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 5.  Deep brain stimulation: are astrocytes a key driver behind the scene?

Authors:  Albert J Fenoy; Laurent Goetz; Stéphan Chabardès; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2014-01-24       Impact factor: 5.243

Review 6.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

7.  Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats.

Authors:  Junfeng Zhang; Hongying Tan; Wei Jiang; Zhiyi Zuo
Journal:  Anesthesiology       Date:  2014-10       Impact factor: 7.892

8.  Microglial regulation of immunological and neuroprotective functions of astroglia.

Authors:  Shih-Heng Chen; Esteban A Oyarzabal; Yueh-Feng Sung; Chun-Hsien Chu; Qingshan Wang; Shiou-Lan Chen; Ru-Band Lu; Jau-Shyong Hong
Journal:  Glia       Date:  2014-08-13       Impact factor: 7.452

9.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 10.  "Targeting astrocytes in CNS injury and disease: A translational research approach".

Authors:  Angela R Filous; Jerry Silver
Journal:  Prog Neurobiol       Date:  2016-03-26       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.